NEWSWIRETODAY Press Release& Newswire Distribution | HOME
MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Written by / Agency / Source: Zinc Ahead Ltd | Veeva Systems
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

ANI Pharmaceuticals Adopts Veeva Commercial Cloud to Better Support Rare Disease Patients - Partnership drives commercial excellence through precision engagement to benefit patients in need of options [Nasdaq: ANIP] - ANIPharmaceuticals.com / Cortrophin.com
ANI Pharmaceuticals Adopts Veeva Commercial Cloud to Better Support Rare Disease Patients

 

NewswireToday - /newswire/ - Baudette, MN, United States, 2022/06/21 - Partnership drives commercial excellence through precision engagement to benefit patients in need of options [Nasdaq: ANIP] - ANIPharmaceuticals.com / Cortrophin.com. NYSE: VEEV

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

ANI Pharmaceuticals, Inc. and Veeva Systems today announced a collaboration to define and operationalize data-driven commercial strategies for ANI’s new Rare Disease Business Unit. ANI is using software, data, and services from Veeva to establish the digital foundation for the launch of the business unit’s first commercially available product in the U.S.

“To serve rare disease patients with high unmet medical needs, we need to be agile, data-driven, and efficient,” said Christopher Mutz, head of rare disease at ANI. “With Veeva as our trusted partner, we accelerated launch readiness and equipped new sales, medical, and marketing teams with the digital tools they need all with the speed and precision warranted by such an important milestone.”

ANI recently announced the U.S. commercial availability of Purified Cortrophin® Gel (Repository Corticotropin Injection USP) 80 U/mL (cortrophin.com). To prepare for this launch, ANI adopted the complete suite of Veeva Commercial Cloud solutions across its business, including software for multichannel engagement and content management, along with longitudinal patient data for customer segmentation.

“ANI now has a digital foundation that supports its patient-centric approach to commercialization,” said Paul Shawah, executive vice president of commercial strategy at Veeva. “The company is advancing its mission by leveraging data to uncover key patient groups as well as the providers who care for them and empowering its field teams to create meaningful connections.”

Veeva Business Consulting also helps the company use advanced analytics to continuously optimize for the most precise and impactful sales and medical interactions. This allows ANI’s field force to identify new healthcare professionals, while delivering actionable insights so they can best engage with them. Learn more about how ANI launched at speed and scale in an upcoming fireside chat webinar on July 19.

About Veeva Systems

Veeva (veeva.com) is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world’s largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves.

About ANI Pharmaceuticals, Inc.

ANI Pharmaceuticals (anipharmaceuticals.com) is a diversified biopharmaceutical company serving patients in need by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceutical products, including for diseases with high unmet medical need. Our team is focused on delivering sustainable growth by building a successful Purified Cortrophin® Gel franchise, strengthening our generics business with enhanced development capability, innovation in established brands and leveraging our North American manufacturing capabilities. For more information, please visit anipharmaceuticals.com.

ANI Forward-Looking Statements
To the extent any statements made in this release relate to information that is not historical, these are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “anticipates,” “will,” “expects,” “plans,” “potential,” “future,” “believes,” “intends,” “continue,” other words of similar meaning, derivations of such words, and the use of future dates. These forward-looking statements include, but are not limited to, statements related to the commercial launch of Cortrophin Gel. Risks and uncertainties that may cause ANI’s actual results to be materially different than those expressed in or implied by such forward-looking statements include, but are not limited to, the costs involved in commercializing Cortrophin Gel, general business and economic conditions, increased competition and strategies employed by competitors, uncertainties regarding the COVID-19 pandemic, market trends for our products, regulatory environment and changes, and other risks and uncertainties that are described in ANI’s Annual Report on Form 10-K, quarterly reports on Form 10-Q, and other periodic reports filed with the U.S. Securities and Exchanges Commission.

Any forward-looking statements in this news release speak only as of the date of this news release and are based on ANI’s current beliefs, assumptions, and expectations. Except as required by law, ANI undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Veeva Forward-looking Statements
This release contains forward-looking statements regarding Veeva’s products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the period ended April 30, 2022, which you can find here (a summary of risks which may impact our business can be found on pages 37 and 38), and in our subsequent SEC filings, which you can access at sec.gov.


Contact:

Deivis Mercado
Veeva Systems
925-226-8821
deivis.mercado[.]veeva.com

ANI Pharmaceuticals Media Contact
Angela Salerno-Robin
dna Communications
212-445-8219
ASalerno-Robin[.]dna-comms.com

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Zinc Ahead Ltd | Veeva Systems

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]  / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


ANI Pharmaceuticals Adopts Veeva Commercial Cloud to Better Support Rare Disease Patients

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Publisher Contact: Deivis Mercado - Veeva.com 
925-226-8821 deivis.mercado[.]veeva.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Zinc Ahead Ltd | Veeva Systems securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Zinc Ahead Ltd | Veeva Systems / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

Bruker’s Arxspan Business for Lab Informatics Expands Customer Capabilities by Joining Tetra Partner Network
Ipsen Announces Results from Phase III RESILIENT Trial Evaluating Onivyde® in Second-line Monotherapy for Small Cell Lung Cancer
Ipsen and Marengo Therapeutics Announce Strategic Partnership to Advance Two Precision Immuno-oncology Candidates from Marengo’s STAR Platform
SCHOTT Establishes Stand-alone Company for its Pharma Business to Promote Further Growth
Bushu Pharma Lauded by Frost & Sullivan for Enabling the Launch of Specialty Drugs in Japan and Asia-Pacific
BASF Expands World-scale Vitamin A Formulation Plant in Ludwigshafen
Ipsen to Acquire Epizyme, Expanding its Portfolio in Oncology
GenScript ProBio and ProteoNic BV Signed a Strategic Cooperation Based on High Expressing Vector System
Ipsen Receives Positive Opinion in Europe for Dysport® in the Management of Urinary Incontinence in Adults
DSM Acquires Brazil’s Leading Animal Nutrition Technology Company to Boost Precision Services Offering
DSM and the World Food Programme Partner to Improve Nutrition Around the World
European Commission Approves Cabometyx® as A Second-line Treatment for People Living with Radioactive Iodine-refractory Differentiated Thyroid Cancer
Shionogi and NEC Enter into Strategic Research Collaboration for Novel Hepatitis B Therapeutic Vaccine
Boehringer Ingelheim Selects Veeva Development Cloud Worldwide to Bring Innovative Therapies to Patients Faster
Ipsen Announces Investment in New State-of-the-art Electronic Autoinjector for Somatuline® Autogel® / Somatuline® Depot (lanreotide)

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  La Bella Bakery Artisan Bakery Arizona





 
  ©2022 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are proudly NOT affiliated with USA TODAY (usatoday.com)